Fc gamma receptor and Complement component 1q (FcγR/C1q)

The Fc gamma receptors (FcγRs) and Complement component 1q (C1q) represent the dual effector pathways of the humoral immune system that are engaged by the Fc region of immunoglobulin G (IgG) antibodies. FcγRs are a family of cell-surface glycoproteins found on immune cells such as natural killer (NK) cells, macrophages, and neutrophils, where they mediate antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) (Source: UniProt, PubMed). Complement component 1q is the initiating protein of the classical complement pathway, which, upon binding to the antibody Fc region, triggers a proteolytic cascade resulting in complement-dependent cytotoxicity (CDC) and the formation of the membrane attack complex (Source: StatPearls, PubMed). These components are the primary targets for the Fc portion of therapeutic monoclonal antibodies, and their engagement is critical for the clearance of tumor cells or pathogens in oncology and infectious disease settings. Conversely, in autoimmune diseases, therapeutic strategies may involve blocking these interactions or using effector-silent antibodies to prevent tissue damage. Genetic variations in these targets, particularly polymorphisms in the FCGR3A and FCGR2A genes, are known to influence the clinical efficacy of drugs like rituximab and trastuzumab. Understanding the interplay between these receptors and the complement system is essential for optimizing antibody design and predicting potential adverse effects like cytokine release syndrome.

Other names

Fc gamma receptorsC1qFc effector moleculesFc-binding proteinsFc receptors and complement C1q

Activation of antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC) through Fc-region binding; or therapeutic inhibition of these pathways.